WO1987003490A3 - Transdermal delivery system - Google Patents

Transdermal delivery system Download PDF

Info

Publication number
WO1987003490A3
WO1987003490A3 PCT/US1986/002584 US8602584W WO8703490A3 WO 1987003490 A3 WO1987003490 A3 WO 1987003490A3 US 8602584 W US8602584 W US 8602584W WO 8703490 A3 WO8703490 A3 WO 8703490A3
Authority
WO
WIPO (PCT)
Prior art keywords
ethyl
hexanediol
carrier
oleic acid
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1986/002584
Other languages
French (fr)
Other versions
WO1987003490A2 (en
Inventor
Nicholas Bodor
Thorsteinn Loftsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Key Pharmaceuticals Inc
Original Assignee
Key Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Key Pharmaceuticals Inc filed Critical Key Pharmaceuticals Inc
Priority to DE8787900446T priority Critical patent/DE3688075T2/en
Priority to AT87900446T priority patent/ATE86870T1/en
Priority to KR1019870700681A priority patent/KR900002653B1/en
Publication of WO1987003490A2 publication Critical patent/WO1987003490A2/en
Publication of WO1987003490A3 publication Critical patent/WO1987003490A3/en
Priority to DK407587A priority patent/DK407587A/en
Priority to MYPI87002301A priority patent/MY102378A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pharmaceutical preparations comprised of a pharmaceutically active ingredient and a carrier which comprises a percutaneous penetration enhancer comprised of 2-ethyl-1, 3-hexanediol and/or oleic acid. The 2-ethyl-1, 3-exanediol may be present in an amount in the range of about 50% to 100% based on the weight of the carrier. The oleic acid may be used in combination with 2-ethyl-1, 3-hexanediol in an amount of about 1 to 40% based on the weight of the carrier to provide a synergistic effect with respect to percutaneous penetration enhancement. The compound 2-ethyl-1, 3-hexanediol as used alone and/or in combination with the oleic acid has been found to significantly enhance the delivery of a drug, to a patient, from a transdermal delivery system.
PCT/US1986/002584 1985-12-06 1986-12-05 Transdermal delivery system Ceased WO1987003490A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE8787900446T DE3688075T2 (en) 1985-12-06 1986-12-05 TRANSDERMAL ADMINISTRATION SYSTEM.
AT87900446T ATE86870T1 (en) 1985-12-06 1986-12-05 TRANSDERMAL DELIVERY SYSTEM.
KR1019870700681A KR900002653B1 (en) 1985-12-06 1986-12-05 Transdermal delivery system
DK407587A DK407587A (en) 1985-12-06 1987-08-05 TRANSDERMAL SUBMISSION SYSTEM
MYPI87002301A MY102378A (en) 1985-12-06 1987-09-29 Transdermal delivery system.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/806,257 US4764381A (en) 1985-12-06 1985-12-06 Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
US806,257 1985-12-06

Publications (2)

Publication Number Publication Date
WO1987003490A2 WO1987003490A2 (en) 1987-06-18
WO1987003490A3 true WO1987003490A3 (en) 1987-07-30

Family

ID=25193671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1986/002584 Ceased WO1987003490A2 (en) 1985-12-06 1986-12-05 Transdermal delivery system

Country Status (11)

Country Link
US (2) US4764381A (en)
EP (2) EP0393727A3 (en)
JP (1) JPS63502108A (en)
KR (1) KR900002653B1 (en)
AT (1) ATE86870T1 (en)
AU (2) AU602324B2 (en)
CA (1) CA1280974C (en)
DE (1) DE3688075T2 (en)
DK (1) DK407587A (en)
MY (1) MY102378A (en)
WO (1) WO1987003490A2 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933184A (en) * 1983-12-22 1990-06-12 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
US4931283A (en) * 1983-12-22 1990-06-05 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
US4983396A (en) * 1985-12-06 1991-01-08 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1,3-hexanediol
US5051260A (en) * 1987-07-16 1991-09-24 The Regents Of The University Of California Method and composition for enhancing the cutaneous penetration of pharmacologically active agents
US4971800A (en) * 1988-07-08 1990-11-20 The Regents Of The University Of California Method and compositions for enhancing the cutaneous penetration of pharmacologically active agents
US5045317A (en) * 1987-07-16 1991-09-03 The Regents Of The University Of California Enhancing the cutaneous penetration of pharmacologically active agents
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
WO1991002553A2 (en) * 1989-08-17 1991-03-07 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
US5262165A (en) * 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
AR246186A1 (en) * 1989-11-17 1994-07-29 Beta Pharm Co Procedure for manufacturing a device for administering stradiol through the skin.
JP2849950B2 (en) * 1990-11-30 1999-01-27 日東電工株式会社 Transdermal formulation
US5202125A (en) * 1990-12-10 1993-04-13 Theratech, Inc. Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes
US5518734A (en) * 1991-09-25 1996-05-21 Beta Pharmaceuticals Co. Transdermal delivery system for estradiol and process for manufacturing said device
US5705185A (en) * 1991-09-25 1998-01-06 Beta Pharmaceuticals Co. Transdermal delivery of estradiol and process for manufacturing said device
JP2960832B2 (en) * 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト Estradiol administration system
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
WO1995006466A1 (en) * 1993-09-01 1995-03-09 Koren Laboratories Pty. Limited Treatment of anorectal disorders
US5552153A (en) * 1994-04-28 1996-09-03 Hoffman-La Roche Inc. Pharmaceutical composition for transdermal delivery
US5580574A (en) * 1994-04-28 1996-12-03 Hoffmann-La Roche Inc. Pharmaceutical composition for transdermal delivery
DK1051972T3 (en) 1994-05-27 2008-01-28 Strakan Int Ltd Nitric oxide donor composition and method for the treatment of anal disorders
FR2732223B1 (en) * 1995-03-30 1997-06-13 Sanofi Sa PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL ADMINISTRATION
US5707612A (en) * 1996-04-08 1998-01-13 Alzo, Inc. Use urethane polymers of castor oil skin and personal care product compositiions
HUP9904109A3 (en) * 1996-10-14 2000-11-28 Kowa Co Ltd Nagoya Shi Local anesthetic for external use
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
IT1294748B1 (en) 1997-09-17 1999-04-12 Permatec Tech Ag FORMULATION FOR A TRANSDERMAL DEVICE
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
WO2005039531A1 (en) * 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
WO2002011768A1 (en) * 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
PT1372708E (en) 2001-02-13 2008-09-29 Us Gov Sec Army Vaccine for transcutaneous immunization against travellers` diarrhoea
US6727287B2 (en) 2001-04-16 2004-04-27 Pts International, Inc. Toluene sulfonamide-containing anti-tumor composition and method of use thereof
DE20107040U1 (en) * 2001-04-24 2002-10-02 Novartis Ag, Basel metering lance
AT411327B (en) * 2001-08-23 2003-12-29 Heil Bettina Fast absorption rectal suppository for treating hormone deficiency, comprises progesterone or its precursor dehydroepiandrosterone and unsaturated, unesterified fatty acid(s)
CA2530407A1 (en) * 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
US7842007B2 (en) 2004-04-30 2010-11-30 Clawson Burrell E Apparatus and methods for isolating human body areas for localized cooling
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
EP2005959B1 (en) * 2006-03-08 2015-01-21 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
NZ571818A (en) * 2006-03-08 2011-10-28 Nihon Nohyaku Co Ltd External pharmaceutical composition comprising luliconazole and an alpha-hydroxycarboxylic acid such as lactic acid, glycolic acid or malic acid.
AU2006339842B2 (en) * 2006-03-08 2012-06-07 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
NZ571460A (en) 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
CA2675797A1 (en) * 2007-01-16 2008-07-24 Dermworx, Incorporated Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic
US9283177B2 (en) * 2007-01-16 2016-03-15 Juventio, Llc Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic
PL2191828T3 (en) * 2007-09-05 2017-02-28 Pola Pharma Inc. Antifungal pharmaceutical composition
US20100204293A1 (en) * 2007-09-05 2010-08-12 Pola Pharma Inc. Pharmaceutical composition
CN101808638B (en) * 2007-09-05 2012-07-25 宝丽制药股份有限公司 Antifungal composition
CA2730787A1 (en) * 2008-07-16 2010-01-21 David M. Cohen Topical drug delivery system
DE102009013469B4 (en) 2009-03-19 2014-04-17 Bubbles And Beyond Gmbh Preparation for external use
KR101409792B1 (en) 2009-04-09 2014-06-19 니혼노야쿠가부시키가이샤 Antimycotic pharmaceutical composition
WO2010117089A2 (en) 2009-04-09 2010-10-14 Pola Pharma Inc. Antimycotic pharmaceutical composition
US8952044B2 (en) 2009-08-25 2015-02-10 Pola Pharma Inc. Antimycotic pharmaceutical composition
ITMI20111284A1 (en) 2011-07-11 2013-01-12 Giovanni Nusca PHARMACEUTICAL COMPOSITION.
PT2897620T (en) 2012-09-21 2020-09-03 Intensity Therapeutics Inc CANCER TREATMENT METHOD
CN106414415A (en) 2014-03-14 2017-02-15 北卡罗来纳大学教堂山分校 Small molecules for inhibiting male fertility
EP3917571A4 (en) 2019-01-31 2022-10-12 Agency For Science, Technology And Research CNX/ERP57 INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CANCER
US20220378729A1 (en) 2019-11-06 2022-12-01 Smartech Topical, Inc. Topical formulations of cyclooxygenase inhibitors and their use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE243661C (en) *
FR1111910A (en) * 1953-11-11 1956-03-06 Boehringer Sohn Ingelheim Process for preparing solidified and moldable masses for cosmetic and pharmaceutical uses
GB2021950A (en) * 1978-06-05 1979-12-12 Riker Laboratories Inc Nitroglycerin carriers and bandages
EP0121712A1 (en) * 1983-03-03 1984-10-17 The Dow Chemical Company Sustained release compositions from cellulose ethers
EP0127468A2 (en) * 1983-05-26 1984-12-05 CASSELLA Aktiengesellschaft Percutaneous pharmaceutical preparations for external use
EP0043738B1 (en) * 1980-07-09 1985-10-02 THE PROCTER & GAMBLE COMPANY Penetrating topical pharmaceutical compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1055518B (en) * 1971-05-18 1982-01-11 Rotta Research Lab TRIPTOFANO DERIVATIVES
DE2707878C2 (en) * 1977-02-24 1986-01-30 Kali-Chemie Pharma Gmbh, 3000 Hannover Use of mono- and / or diglycerides of medium-chain fatty acids
SE445174B (en) * 1978-03-07 1986-06-09 Sandoz Ag PHARMACEUTICAL COMPOSITION CONTAINING A CYCLOSPORIN AND A HEALING SUBSTANCE
US4241084A (en) * 1979-08-30 1980-12-23 Minuto Maurice M Antibacterial and antifungal compositions
CA1163561A (en) * 1979-11-06 1984-03-13 Cyril Boroda Preparation containing nitroglycerine and optionally other medicaments and preparation thereof
US4305936A (en) * 1980-10-09 1981-12-15 Dermik Laboratories Topical corticosteroid formulations
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4440777A (en) * 1981-07-07 1984-04-03 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
US4522872A (en) * 1982-04-12 1985-06-11 Milliken Research Corporation Industrial fabrics
US4605548A (en) * 1983-05-31 1986-08-12 Nitto Electric Industrial Co., Ltd. Drug administration material
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
DE3685895T2 (en) * 1985-02-25 1992-12-24 Univ Rutgers DOSING SYSTEM FOR TRANSDERMAL ABSORPTION OF DRUG ACTIVE SUBSTANCES.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE243661C (en) *
FR1111910A (en) * 1953-11-11 1956-03-06 Boehringer Sohn Ingelheim Process for preparing solidified and moldable masses for cosmetic and pharmaceutical uses
GB2021950A (en) * 1978-06-05 1979-12-12 Riker Laboratories Inc Nitroglycerin carriers and bandages
EP0043738B1 (en) * 1980-07-09 1985-10-02 THE PROCTER & GAMBLE COMPANY Penetrating topical pharmaceutical compositions
EP0121712A1 (en) * 1983-03-03 1984-10-17 The Dow Chemical Company Sustained release compositions from cellulose ethers
EP0127468A2 (en) * 1983-05-26 1984-12-05 CASSELLA Aktiengesellschaft Percutaneous pharmaceutical preparations for external use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 82, No. 5, 3 February 1975, (Columbus, Ohio, US) F. STENBACK et al.: "Lack of Toxicity and Carcinogenicity of some Commonly used Cutaneous Agents", see page 133, Abstract 26785c, & Toxicol. Appl. Pharmacol. 1974, 30 (1), 7-13 *

Also Published As

Publication number Publication date
AU602324B2 (en) 1990-10-11
DE3688075D1 (en) 1993-04-22
KR900002653B1 (en) 1990-04-21
AU6733687A (en) 1987-06-30
EP0250542B1 (en) 1993-03-17
EP0393727A2 (en) 1990-10-24
US4885174A (en) 1989-12-05
JPS63502108A (en) 1988-08-18
DE3688075T2 (en) 1993-06-24
CA1280974C (en) 1991-03-05
AU6115890A (en) 1991-02-07
EP0393727A3 (en) 1990-11-22
DK407587D0 (en) 1987-08-05
WO1987003490A2 (en) 1987-06-18
DK407587A (en) 1987-08-05
EP0250542A1 (en) 1988-01-07
ATE86870T1 (en) 1993-04-15
KR880700675A (en) 1988-04-11
US4764381A (en) 1988-08-16
MY102378A (en) 1992-06-17
AU625830B2 (en) 1992-07-16

Similar Documents

Publication Publication Date Title
MY102378A (en) Transdermal delivery system.
HU9401107D0 (en) Enhanced skin penetration system for improved topical delivery of drugs
EP0164998A3 (en) Compositions and methods of enhancing transdermal and transmembrane penetration of topical and systemic agents
WO1995001167A3 (en) Incorporating poly-n-vinyl amide in a transdermal system
IE890921L (en) Pharmaceutical composition for systemic transdermal administration
MY109727A (en) Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
ES2053882T3 (en) METHOD FOR REDUCING SKIN IRRITATION ASSOCIATED WITH STRENGTHENING COMPOSITIONS OF PHARMACEUTICAL PENETRATION.
CA2095223A1 (en) Topical compositions for transdermal delivery of prodrug derivatives of morphine
IL76932A (en) Synergistic pharmaceutical analgesic compositions containing dihydrocodeine and ibuprofen
EP1393730A3 (en) Combination chemotherapy involving topotecan and a platinum coordination compound
CA2132865A1 (en) Transdermal administration of oxybutynin
FR2635265B1 (en) INTRAVENOUS PHARMACEUTICAL COMPOSITION COMPRISING CYCLOSPORIN AS ACTIVE INGREDIENT AND PROCESS FOR THE PREPARATION THEREOF
CA2244089A1 (en) Dermal penetration enhancers and drug delivery systems involving same
EP0165696A3 (en) Improved transdermal dosage form
ZA866917B (en) Transdermal aqueous aryl-propionic-acid derivatives medication and methods of preparing same
IE873125L (en) Benzimidazole derivatives
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
CA2284774A1 (en) Theobromine antitussive compositions
CA2173147A1 (en) Anti-obesity agent
EP0620004A4 (en) Medicinal composition.
ATE69724T1 (en) SELF-ADHESIVE DEVICE FOR TRANSDERMAL DELIVERY OF A DRUG.
AU1950388A (en) Pharmaceutical formulation ensuring the transdermal absorption of the active ingredient and process for preparing same
UA40636C2 (en) pharmaceutical composition containing, as the active ingredient, an association of acetylsalicylic acid and metoclopramide, pharmaceutical medication in the form of powder and method for its preparation
CA2118512A1 (en) Agents for treating substance abuse disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU DK JP KR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1987900446

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AU DK JP KR

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWP Wipo information: published in national office

Ref document number: 1987900446

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1987900446

Country of ref document: EP